Module 1: Influenza – Virus and Disease >>
Detailed epidemiological information including morbidity/mortality, virus and structure, relationship to epidemics and pandemics, and therapeutic options in management of influenza.

Module 2: Diagnosis of Influenza >>
Practical information about key symptoms, differentiation from other respiratory conditions, surveillance activities and available diagnostic tests to facilitate appropriate empiric therapy and improve patient care.

Module 3:  FluSTAR™ System for Tracking and Reporting Flu >> Coming Soon
Timely information about current levels of influenza in the community is key in accurate early diagnosis and management of influenza.  FluSTAR provides crucial, timely information countrywide on the status of influenza.  Learn more.

Module 4: Selective Neuraminidase Inhibitors – Mechanism of Action >>
A comprehensive look at the influenza virus surface proteins; their contribution to viral dissemination; and how they relate to the mechanism of selective neuraminidase inhibition and its effectiveness against influenza A and B.

Module 5: Tamiflu (oseltamivir phosphate) Influenza B: An Overview >>
Concise profile of oseltamivir, microbiology, clinical pharmacology, usage, contraindications, precautions, adverse reactions, dosage and administration.  Highlights of clinical trials in influenza B.

Module 6: Tamiflu® (oseltamivir phosphate): The Only Oral Antiviral for the Management of Influenza A and B >>
Pharmacology and pharmacokinetic profile of oseltamivir, pivotal studies for management of influenza with oseltamivir, and important medical issues surrounding resistance and safety.

Module 7: Tamiflu® (oseltamivir phosphate) for Prevention of Influenza >>
Clinical trial experience: Postexposure prophylaxis with Tamiflu in healthy unvaccinated patients exposed to an influenza-infected index case. Also, seasonal prophylaxis in healthy adults and a vaccinated nursing home population.

Module 8:  Tamiflu® (oseltamivir phosphate) for the Treatment and Prophylaxis of Pediatric Influenza >>
A comprehensive look at the scope of disease burden of pediatric influenza.  Diagnosis and antiviral use in children, efficacy and safety data from Tamiflu pediatric trials.

True Flu: A True Diagnostic Challenge

Tamiflu Dosing Card

Roche is a pioneer in providing our drugs, free, to patients who lack prescription coverage and the means to pay for the medications they need. In fact, the Roche Patient Assistance Program was one of the first in the industry, setting the standard for assisting patients in need since the early 1960.

Since 2000, the Roche Patient Assistance Foundation provided free Roche products to patients in need valued at $671,770,812 (based on Wholesale Acquisition Cost or list price). This includes products provided through generous programs to support Xeloda?(capecitabine) and other Roche products.

Roche does not charge a co-payment or limit the time a patient may receive free drug. We are committed to making sure every patient who needs our drug gets it, whether that patient is a senior citizen with cancer, or a member of a working family facing an organ transplant.

To learn more about the Roche Patient Assistance Foundation and the individual product programs, call our toll-free number 1-877-75ROCHE (877-757-6243) and to find access the extensive list of pharmaceutical industry patient assistant programs, access www.pparx.org.

April 2007 (For rocheusa.com)

View All Professional Sites »